What doctors should consider before prescribing e‐liquids for e‐cigarettes

Miranda P Ween, David G Chapman and Alexander N Larcombe
Med J Aust 2022; 216 (1): . || doi: 10.5694/mja2.51351
Published online: 29 November 2021

An Australian standard for prescribing e‐cigarette nicotine has arrived — are you prepared with the facts?

Various nicotine replacement therapies (NRTs) have been approved by the Therapeutic Goods Administration (TGA) as safe and effective smoking cessation aids. However, many smokers are now turning to electronic cigarettes (e‐cigarettes) to reduce their tobacco consumption, even though there is a lack of clear, unbiased data on whether, and how effectively, e‐cigarettes aid tobacco smoking cessation.1 There is also growing evidence that they may cause harm.2 Emerging evidence shows concurrent use of tobacco cigarettes and e‐cigarettes may be worse than either just smoking or just vaping, particularly for cardiovascular health.2

  • 1 Royal Adelaide Hospital, Adelaide, SA
  • 2 University of Adelaide, Adelaide, SA
  • 3 Royal North Shore Hospital, Sydney, NSW
  • 4 University of TechnologySydney, Sydney, NSW
  • 5 Telethon Kids Institute, Perth, WA
  • 6 Curtin University, Perth, WA

Competing interests:

No relevant disclosures.

  • 1. Chan GCK, Stjepanović D, Lim C, et al. A systematic review of randomized controlled trials and network meta‐analysis of e‐cigarettes for smoking cessation. Addictive Behaviors 2021; 119: 106912.
  • 2. Bozier J, Chivers EK, Chapman DG, et al. The evolving landscape of e‐cigarettes: a systematic review of recent evidence. Chest 2020; 157: 1362–1390.
  • 3. Federal Register of Legislation. Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Order 2021. (viewed Oct 2021).
  • 4. Royal Australian College of General Practitioners. Supporting smoking cessation: a guide for health professionals. Last revised: 29 Sept 2021.‐resources/clinical‐guidelines/key‐racgp‐guidelines/view‐all‐racgp‐guidelines/supporting‐smoking‐cessation (viewed Oct 2021).
  • 5. European Parliament and Council of the European Union. Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014. https://eur‐‐content/EN/TXT/?uri=CELEX%3A02014L0040‐20150106 (viewed Oct 2021).
  • 6. Voos N, Goniewicz ML, Eissenberg T. What is the nicotine delivery profile of electronic cigarettes? Expert Opin Drug Deliv 2019; 16: 1193–203.
  • 7. Goldenson NI, Leventhal AM, Stone MD, et al. Associations of electronic cigarette nicotine concentration with subsequent cigarette smoking and vaping levels in adolescents. JAMA Pediatr 2017; 171: 1192–1199.
  • 8. Soar K, Kimber C, McRobbie H, et al. Nicotine absorption from e‐cigarettes over 12 months. Addictive Behaviors 2019; 91: 102–105.
  • 9. Cobb CO, Foulds J, Yen MS, et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco‐related toxicant exposure: a four‐arm, parallel‐group, randomised, controlled trial. Lancet Respir Med 2021; 9: P840–850.
  • 10. Rüther T, Hagedorn D, Schiela K, et al. Nicotine delivery efficiency of first‐ and second‐generation e‐cigarettes and its impact on relief of craving during the acute phase of use. International Journal of Hygiene and Environmental Health 2018; 221: 191–198.
  • 11. Hajek P, Phillips‐Waller A, Przulj D, et al. A randomized trial of e‐cigarettes versus nicotine‐replacement therapy. New England Journal of Medicine 2019; 380: 629–637.
  • 12. Sahr M, Kelsh SE, Blower N. Pharmacist assisted vape taper and behavioral support for cessation of electronic nicotine delivery system use. Clin Case Rep 2020; 8: 100–103.
  • 13. Leventhal AM, Goldenson NI, Barrington‐Trimis JL, et al. Effects of non‐tobacco flavors and nicotine on e‐cigarette product appeal among young adult never, former, and current smokers. Drug and Alcohol Dependence 2019; 203: 99–106.
  • 14. St Helen G, Dempsey DA, Havel CM, et al. Impact of e‐liquid flavors on nicotine intake and pharmacology of e‐cigarettes. Drug and Alcohol Dependence 2017; 178: 391–398.
  • 15. Benowitz NL, Herrera B, Jacob P, 3rd. Mentholated cigarette smoking inhibits nicotine metabolism. Journal of Pharmacology and Experimental Therapeutics 2004; 310: 1208–1215.
  • 16. Cooper SY, Henderson BJ. The impact of electronic nicotine delivery system (ENDS) flavors on nicotinic acetylcholine receptors and nicotine addiction‐related behaviors. Moleclules 2020; 25: 4223.
  • 17. Erinoso O, Clegg Smith K, Iacobelli M, et al. Global review of tobacco product flavour policies. Tob Control 2020; 30: 373–379.
  • 18. Cooper SY, Akers AT, Henderson BJ. Green apple e‐cigarette flavorant farnesene triggers reward‐related behavior by promoting high‐sensitivity nAChRs in the ventral tegmental area. eNeuro 2020; 7: ENEURO.0172‐20.2020.
  • 19. Hobkirk AL, Houser KR, Hoglen B, et al. Evidence from an fMRI study that dessert‐flavored e‐cigarettes engage taste‐related, but not smoking‐related, brain circuitry for female daily smokers. Exp Clin Psychopharmacol 2021; [Online ahead of print].


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.